Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors-Reference-Cited by-同舟云学术

Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors

Published:2015-05-11 Issue:17 Volume:6 Page:15425-15435
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Schwermer Melanie¹,Lee Sangkyun²,Köster Johannes³,van Maerken Tom⁴,Stephan Harald¹,Eggert Angelika⁵,Morik Katharina²,Schulte Johannes H.¹⁶⁷⁸⁹,Schramm Alexander¹

Affiliation:

1. Department of Pediatric Oncology and Hematology, University Children's Hospital Essen, Essen, Germany

2. Department of Computer Sciences, TU Dortmund University, Dortmund, Germany

3. Department of Genome Informatics, University Hospital Essen, Essen, Germany

4. Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium

5. Charite University Medicine, Berlin, Germany

6. Centre for Medical Biotechnology, University Duisburg-Essen, Essen, Germany

7. Translational Neuro-Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany

8. German Cancer Consortium (DKTK), Heidelberg, Germany

9. German Cancer Research Center (DKFZ), Heidelberg, Germany

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysregulation of deubiquitination in breast cancer;Gene;2024-04

2. Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent;International Journal of Molecular Sciences;2023-11-16

3. Targeting CDK1 in cancer: mechanisms and implications;npj Precision Oncology;2023-06-13

4. Network and functional analyses of differentially expressed genes in gastric cancer provide new biomarkers associated with disease pathogenesis;Journal of the Egyptian National Cancer Institute;2023-04-10

5. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16